Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years

NCT01511250 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
360
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Takeda